Valuation: Acrux Limited

Market Cap 6.16M 4.3M 3.76M 3.47M 3.2M 6.03M 414M 41.45M 16.3M 203M 16.15M 15.8M 698M P/E 2024
-3.44x
P/E 2025 -0.95x
Enterprise Value 8.93M 6.24M 5.45M 5.03M 4.64M 8.74M 601M 60.11M 23.64M 294M 23.42M 22.91M 1.01B EV / Sales 2024
4.09x
EV / Sales 2025 7.81x
Free-Float
78.27%
Yield 2024 *
-
Yield 2025 -
1 day+4.35%
1 week+4.35%
1 month-20.00%
3 months+9.09%
6 months-17.24%
Current year-20.00%
1 week 0.01
Extreme 0.011
0.01
1 month 0.01
Extreme 0.011
0.02
Current year 0.01
Extreme 0.009
0.02
1 year 0.01
Extreme 0.009
0.02
3 years 0.01
Extreme 0.009
0.1
5 years 0.01
Extreme 0.009
0.14
10 years 0.01
Extreme 0.009
0.84
Manager TitleAgeSince
Chief Executive Officer - 01/06/2025
Director of Finance/CFO - 21/06/2021
Chief Tech/Sci/R&D Officer - 15/02/2015
Director TitleAgeSince
Chairman 74 01/01/2006
Director/Board Member - 01/10/2013
Director/Board Member 70 01/06/2016
Change 5-day change 1-year change 3-year change Capi.($)
+4.35%+4.35%-25.00%-76.00% 4.3M
-0.90%-0.15%+13.46%+79.34% 48.15B
-0.23%-1.65%+65.14%+115.81% 35.59B
-0.76%-1.44%-4.30%+37.38% 11.9B
-0.88%-0.62%+16.38%+89.65% 11.85B
+0.19%+2.87%+34.92%+127.54% 9.31B
-0.75%-0.91%+18.26%+37.23% 6.91B
-9.93%+0.35%-29.90%+14.89% 6.13B
+3.37%-0.10%+49.31%-4.38% 7.02B
-2.25%-2.08%+0.40%+218.27% 6.55B
Average -0.78%+0.49%+13.87%+63.97% 14.34B
Weighted average by Cap. -0.88%-0.42%+25.98%+86.35%

Financials

2024 2025
Net sales 5.09M 3.55M 3.11M 2.87M 2.64M 4.98M 342M 34.26M 13.48M 168M 13.35M 13.06M 577M 1.19M 831K 726K 670K 618K 1.16M 80.02M 8.01M 3.15M 39.19M 3.12M 3.05M 135M
Net income -5.8M -4.05M -3.54M -3.27M -3.01M -5.67M -390M -39.04M -15.35M -191M -15.21M -14.88M -658M -5.94M -4.15M -3.63M -3.35M -3.09M -5.82M -400M -40.01M -15.74M -196M -15.59M -15.25M -674M
Net Debt 759K 530K 463K 427K 394K 743K 51.04M 5.11M 2.01M 25M 1.99M 1.95M 86.05M 2.77M 1.94M 1.69M 1.56M 1.44M 2.71M 186M 18.66M 7.34M 91.29M 7.27M 7.11M 314M
Logo Acrux Limited
Acrux Limited is an Australia-based specialty pharmaceutical company. The Company is engaged in developing and commercializing a pipeline of topically applied pharmaceutical products. Its products include Lidocaine and Prilocaine Cream, USP 2.5%/2.5%, Lenzetto, Evamist, Dapsone Gel, 5% and Testosterone Topical Solution, 30 mg / 1.5 ml. Lidocaine and Prilocaine Cream USP (a eutectic mixture of lidocaine 2.5% and prilocaine 2.5%) is indicated as a topical anesthetic for use on normal intact skin for local analgesia and genital mucous membranes for superficial minor surgery and as pretreatment for infiltration anesthesia. Lenzetto (estradiol 1.53 mg/spray, transdermal spray, solution) is an estradiol spray for women which is used to treat moderate to severe hot flushes commonly associated with menopause. Testosterone Topical Solution is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.
Employees
43
Date Price Change Volume
16/07/26 A$0.0120 +4.35% 423,652
14/07/26 A$0.0115 +4.55% 2,185
13/07/26 A$0.0110 -4.35% 2,188

Annual profits - Rate of surprise